JAMES GRISOLIA: Open Payments
NPI 1336102359 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,507 in 54 payments from 16 companies in 2025. Trend: 2023 $899 · 2024 $1,614 · 2025 $1,507
Food & beverage: $1,507
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 12 | $381 |
| Alexion Pharmaceuticals, Inc. | 9 | $219 |
| Axsome Therapeutics, Inc. | 3 | $162 |
| Biogen, Inc. | 5 | $123 |
| LivaNova USA, Inc. | 5 | $118 |
| Neurelis, Inc. | 4 | $87 |
| PFIZER INC. | 3 | $67 |
| Eisai Inc. | 2 | $65 |
| ABIOMED | 2 | $60 |
| Amgen Inc. | 2 | $56 |
Products named: ULTOMIRIS, LEQEMBI, Zilbrysq, Nayzilam, Auvelity, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VALTOCO, Fintepla.
Industry payments across CA — which companies pay providers there.
